Everest Medicines Expands its 2019 Collaboration with Calliditas to Develop and Commercialize Nefecon for Primary IgA Nephropathy in South Korea
Shots:
- Calliditas to receive $3M in initial up front upon the signing of the agreement. The companies will enhance their international commercial footprint, following the expansion of license agreement
- The agreement follows the June 2019 exclusive, royalty-bearing license agreement where Everest got exclusive rights to develop & commercialize Nefecon for IgAN in Mainland China, Hong Kong, Macau, Taiwan & Singapore
- Everest will collaborate with the KFDA for the regulatory filings and an NDA for Nefecon to treat primary IgAN in the coming mos. Nefecon is an oral, delayed-release formulation of budesonide that undergoes substantial first-pass metabolism & was approved in the US under accelerated approval
Ref: PR Newswire | Image: Everest Medicines
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
